Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
NCT01003379 is registered in ClinicalTrials.gov with Targacept Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia
- Lead sponsor
- Targacept Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- December 31, 2010
- Enrollment
- 184 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.